0001562180-20-004471.txt : 20200612
0001562180-20-004471.hdr.sgml : 20200612
20200612200943
ACCESSION NUMBER: 0001562180-20-004471
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200611
FILED AS OF DATE: 20200612
DATE AS OF CHANGE: 20200612
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doogan Declan
CENTRAL INDEX KEY: 0001704234
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38080
FILM NUMBER: 20961708
MAIL ADDRESS:
STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP
STREET 2: 234 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-06-11
false
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
BHVN
0001704234
Doogan Declan
C/O BIOHAVEN PHARMACEUTICALS
215 CHURCH STREET
NEW HAVEN
CT
06510
true
false
false
false
Common Shares
2020-06-11
4
S
false
16444.00
61.9672
D
909558.00
I
By the Declan Doogan 2014 Trust
Common Shares
2020-06-11
4
S
false
20043.00
62.7754
D
889515.00
I
By the Declan Doogan 2014 Trust
Common Shares
2020-06-11
4
S
false
18474.00
63.794
D
871041.00
I
By the Declan Doogan 2014 Trust
Common Shares
2020-06-11
4
S
false
25039.00
64.5742
D
846002.00
I
By the Declan Doogan 2014 Trust
Common Shares
2020-06-12
4
S
false
7600.00
62.9279
D
838402.00
I
By the Declan Doogan 2014 Trust
Common Shares
2020-06-12
4
S
false
18400.00
63.9004
D
820002.00
I
By the Declan Doogan 2014 Trust
Common Shares
2020-06-12
4
S
false
28086.00
64.7897
D
791916.00
I
By the Declan Doogan 2014 Trust
Common Shares
2020-06-12
4
S
false
25914.00
65.7849
D
766002.00
I
By the Declan Doogan 2014 Trust
Common Shares
373913.00
D
These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.31 - $62.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.31 - $63.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.31 - $64.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.32 - $62.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.32 - $64.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 - $65.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
/s/ Jim Engelhart, Attorney-in-Fact
2020-06-12